Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03520868 · ClinicalTrials.gov registry record
Heparin Requirements in Patients Undergoing Atrial Fibrillation Ablation on Coumadin vs NOACs
A clinical trial, sponsored by Steward St. Elizabeth's Medical Center of Boston.
- Completed
- Registry status
- 60
- Enrollment target
NCT03520868: Completed study, sponsored by Steward St. Elizabeth's Medical Center of Boston.
NCT03520868 is a clinical trial that has completed, run by Steward St. Elizabeth's Medical Center of Boston. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03520868 has completed, sponsored by Steward St. Elizabeth's Medical Center of Boston.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
To observe, using a prospectively designed study, the effect of type of oral anticoagulant on intra-procedural heparin requirements in patients undergoing Atrial Fibrillation ablation and to assess whether ACT assay accurately reflects heparin anti coagulation effect.
Primary Outcome
The investigators will measure the amount of intravenous heparin administered to each patient during the afib ablation to achieve therapeutic anticoagulation.
Interventions
- DIAGNOSTIC_TEST Monitoring Anti Factor Xa level
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-05-05 |
| Est. Completion | 2020-03-30 |
What the finished NCT03520868 record still lists
NCT03520868 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Monitoring Anti Factor Xa level is the first listed.
NCT03520868 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03520868 about?
NCT03520868 is a clinical study titled "Heparin Requirements in Patients Undergoing Atrial Fibrillation Ablation on Coumadin vs NOACs". To observe, using a prospectively designed study, the effect of type of oral anticoagulant on intra-procedural heparin requirements in patients undergoing Atrial Fibrillation ablation and to assess whether ACT assay accurately reflects heparin anti coagulation effect.
What is the current status of trial NCT03520868?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2017-05-05. Estimated completion is 2020-03-30.
What interventions are being tested in trial NCT03520868?
The interventions under investigation include: Monitoring Anti Factor Xa level (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03520868?
This trial is sponsored by Steward St. Elizabeth's Medical Center of Boston, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI